Ontario’s plunging price-caps on generics: deeper dives may drown some drugs

In April 2010, the Ontario government announced another reduction in the maximum price of generic drugs permitted under the Ontario Drug Benefit (ODB) program, demanding that generic drugs now be sold for no more than 25% of the branded product’s price. Other provinces are following Ontario in setting unprecedentedly low price-caps to reduce the cost of generic drugs. Generic product substitution legislation is vital to reducing costs to provincial drug plans, yet lower and lower price-caps may undo some of the benefits of substitution legislation if generics find it difficult to survive.

[1]  M. Hollander.  British Columbia Ministry of Health Services and the General Practice Services Committee , 2013 .

[2]  J. Puig-Junoy.  Impact of European Pharmaceutical Price Regulation on Generic Price Competition , 2012, PharmacoEconomics.

[3]  A. Anis,et al.  Ontario’s plunging price-caps on generics: deeper dives may drown some drugs , 2011, Open medicine : a peer-reviewed, independent, open-access journal.

[4]  E. Berndt,et al.  Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation , 2010 .

[5]  J. Lexchin.  Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. , 2009, Health policy.

[6]  L. Bulfone,et al.  High prices for generics in Australia - more competition might help. , 2009, Australian health review : a publication of the Australian Hospital Association.

[7]  Michael F Furukawa,et al.  International prices and availability of pharmaceuticals in 2005. , 2008, Health affairs.

[8]  S. Simoens.  International comparison of generic medicine prices , 2007, Current medical research and opinion.

[9]  E. Berndt,et al.  Authorized generic drugs, price competition, and consumers' welfare. , 2007, Health affairs.

[10]  M. Furukawa,et al.  Prices and availability of biopharmaceuticals: an international comparison. , 2006, Health affairs.

[11]  J. Avorn,et al.  A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences , 2006, Clinical pharmacology and therapeutics.

[12]  M. Furukawa,et al.  Prices and availability of pharmaceuticals: evidence from nine countries. , 2003, Health affairs.

[13]  A. Anis,et al.  Lowering Generic Drug Prices: Less Regulation Equals More Competition , 2003, Medical care.

[14]  P. Danzon,et al.  Cross-national price differences for pharmaceuticals: how large, and why? , 2000, Journal of health economics.

[15]  A. Anis.  Substitution Laws, Insurance Coverage, and Generic Drug Use , 1994, Medical care.

[16]  A. Anis.  Pharmaceutical Prices with Insurance Coverage and Formularies , 1992 .